Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address a stubborn procedural problem: sealing a much larger arterial puncture without creating a fresh mess.
A Promising Result, Not a Victory Lap
FASTEN was prospective, multicenter, and conducted across six sites in Australia, Belgium, and the Netherlands. Those are sensible ingredients for an early device study. An independent clinical events committee adjudicated the primary safety endpoint, which matters. Device makers should not be grading their own homework on complications if anyone wants the result taken seriously.
The reported safety figure is strong: 98.1% freedom from major target-limb access-site complications through 30 days, listed as 52 of 53 evaluable patients. Freedom from minor access-site complications was also 98.1%, again 52 of 53. Mean time to hemostasis was 0.5 plus or minus 2.0 minutes, while the median was zero minutes. In plain English, the system appears to have achieved bleeding control immediately in a substantial share of cases.
That is the kind of operational outcome physicians notice. TAVR has become more routine, but large-bore femoral access remains a real vulnerability. Bleeding, vascular injury, rescue maneuvers, and longer recovery can erase some of the elegance of a minimally invasive valve procedure. Nobody in a cath lab needs a lecture about that.
The Numbers That Deserve a Second Read
Still, this is a 55-patient, single-arm study. There is no randomized comparison against the established practice of using multiple small-bore suture closure devices, nor against an implant-based closure approach. Without that, FASTEN cannot tell us whether Ladera is better, merely that the observed results were encouraging in this selected cohort.
- Technical success was 94.5%, or 52 of 55 patients.
- Treatment success was 94.3%, or 50 of 53 evaluable patients.
- Mean time to ambulation was 14.3 plus or minus 14.5 hours.
- The primary safety and minor-complication results use 53-patient denominators, despite 55 total enrollments.
That denominator shift is not necessarily alarming; clinical studies often have endpoint-specific evaluability rules. But it is exactly the sort of detail that ought to be explained clearly in a fuller scientific presentation or publication. A 98.1% rate sounds crisp, yet one event in a small study moves the percentage quite a bit. This is why investors and clinicians alike should resist treating a rounded headline statistic like a final verdict.
Why the Design Could Matter in Practice
Ladera's pitch is straightforward enough. Its device is designed for 10F to 24F arteriotomies with one suture-mediated system, using either a pre-close or post-close approach. It deploys two parallel sutures simultaneously and maintains guidewire access during closure. The retained guidewire is not a marketing garnish. When closure gets complicated, preserving a bailout route can be a meaningful procedural advantage.
Current large-bore workflows can require two or more devices intended for smaller punctures, or a system that leaves material inside the artery. The argument for a single-device suture solution is practical: fewer steps, less hardware, no large implant left behind, and potentially a more repeatable workflow. Of course, “potentially” is doing some work there. Ease of use across many operators and anatomies has to be proved beyond an early multicenter experience.
Fast hemostasis is useful, but reproducible closure under real-world pressure is the bar that matters.
What the Sector Should Watch Next
The backdrop is favorable. Transfemoral TAVR/TAVI continues expanding, and larger-bore transcatheter procedures are an important cardiovascular device category. A closure technology that reliably trims access-site trouble could have genuine clinical and commercial relevance. Yet the company is private, and the Ladera Large Bore Closure System remains investigational under federal law and is not available for sale anywhere.
That last fact should cool any urge to sprint ahead of the evidence. There is no sales ramp to model, no approved-market share to claim, and no indication here of timing for regulatory clearance. The next useful proof points would be larger cohorts, transparent accounting for all enrolled patients, comparison with current closure strategies, and evidence that results hold up outside experienced study sites.
For the moment, FASTEN reads like a credible early signal rather than a finished story. Ladera has put forward a device concept that fits a visible clinical need, and the reported 30-day safety and hemostasis data are plainly encouraging. The hard part, as usual in medtech, is carrying that tidy trial-room result into broader, less forgiving clinical reality.